SG Americas Securities LLC Buys 12,599 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

SG Americas Securities LLC boosted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 56.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,097 shares of the company's stock after acquiring an additional 12,599 shares during the quarter. SG Americas Securities LLC owned 0.06% of Harmony Biosciences worth $1,165,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Financial Management Professionals Inc. acquired a new position in Harmony Biosciences during the first quarter worth $29,000. GF Fund Management CO. LTD. acquired a new position in Harmony Biosciences during the fourth quarter worth $41,000. PNC Financial Services Group Inc. increased its stake in shares of Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after buying an additional 519 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Harmony Biosciences by 222.9% in the first quarter. GAMMA Investing LLC now owns 2,929 shares of the company's stock valued at $97,000 after buying an additional 2,022 shares in the last quarter. Finally, Virtus Investment Advisers Inc. acquired a new stake in shares of Harmony Biosciences in the fourth quarter valued at $124,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Trading Down 1.8%

HRMY stock traded down $0.59 during midday trading on Friday, reaching $31.89. The stock had a trading volume of 662,452 shares, compared to its average volume of 624,800. The business has a fifty day simple moving average of $32.59 and a two-hundred day simple moving average of $33.97. The company has a quick ratio of 3.63, a current ratio of 3.67 and a debt-to-equity ratio of 0.22. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 12.17, a PEG ratio of 0.47 and a beta of 0.87. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a return on equity of 24.32% and a net margin of 20.53%. The firm had revenue of $184.73 million for the quarter, compared to analysts' expectations of $184.26 million. During the same quarter last year, the business earned $0.67 earnings per share. The company's revenue was up 19.5% compared to the same quarter last year. As a group, research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Needham & Company LLC restated a "buy" rating and issued a $49.00 target price on shares of Harmony Biosciences in a research note on Tuesday, May 6th. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. UBS Group lowered their target price on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Monday, April 28th. Oppenheimer assumed coverage on Harmony Biosciences in a research note on Monday, June 2nd. They issued an "outperform" rating and a $61.00 target price for the company. Finally, Cantor Fitzgerald upgraded Harmony Biosciences to a "strong-buy" rating in a research note on Tuesday, May 13th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $53.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.